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I. ABSTRACT                                                                                                           
Author: Anita R. Gandhi 
Advisors: Ramon Bataller, Veronica Massey 
Background: Alcoholic Hepatitis (AH) is the most severe form of alcoholic liver 
disease. To identify targets that may be dysregulated in AH, AH patient tissue samples 
were deep-sequenced, identifying that AKR1B10 is the most up-regulated and SORD is 
down-regulated.  
Aims: To use both in vivo and in vitro models to study the induction of AKR1B10 and 
SORD mRNA in response to exposure to ethanol or signaling factors.   
Methods: AKR1B10 and SORD mRNA expression were analyzed in patients with 
various liver diseases, HepG2 cells, VL-17A cells, primary human hepatocytes, and 
ethanol-fed mice. RNA was extracted from all samples and gene expression was both 
measured and analyzed using real-time qPCR.  
Results: AKR1B10 mRNA expression is inducible by EGF in HepG2 cells and primary 
human hepatocytes. It is also up-regulated in the presence of ethanol in VL-17A cells. 
SORD mRNA expression was not significantly changed in any of the in vitro models 
studied, but is up regulated by ethanol exposure in the in vivo mouse model.  
Conclusion: AKR1B10 mRNA induction by ethanol and EGF indicates that ethanol or 
EGF signaling may play a role in the up-regulation of AKR1B10 in patients with AH. In 
addition, due to the lack of significant changes in SORD mRNA expression in the in vitro 
models studied, it is important to identify other signaling factors that may dysregulate 
AKR1B10 or SORD expression, perform co-cultures, perform additional ethanol 
exposure experiments, and measure sorbitol levels in patients with AH. 
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II. INTRODUCTION 
Alcoholic Hepatitis  
Alcohol is a widely consumed substance around the world. Given that the liver is the 
primarily site of alcohol metabolism, over-consumption of alcohol can lead to many 
negative effects on the liver.  Indeed, heavy alcohol drinkers are at a greater risk of 
developing a multitude of liver-specific adverse health conditions, such as alcoholic liver 
disease (ALD).  ALD is a spectrum of disease states, which include steatosis, cirrhosis, 
fibrosis, and alcoholic hepatitis (AH), which is the most severe form of ALD (1).  Though 
AH presents after the onset of the first three diseases, not all patients reach this state.  It is 
unknown as to why some patients develop alcoholic hepatitis and others do not despite a 
similar history of alcohol use.  However AH has become a worldwide problem. 
Apparently, liver cirrhosis has become one of the top causes of death in the United States, 
and almost half of them were alcohol related (1). Despite the prevalence of this condition, 
more research needs to be conducted on the pathogenesis or patient susceptibility to AH, 
as both are still largely unknown.  Additionally, the current therapy for AH, 
corticosteroids, is ineffective in many patients with AH (1).  Therefore, a major goal of our 
research group is to explore the potential mechanisms underlying AH and find targets for 
therapy. In order to do so, our group has previously deep-sequenced genes in individuals 
diagnosed with alcoholic hepatitis and compared gene expression to normal liver tissue. 
The deep sequencing analysis identified aldo-keto reductase family 1 member B10 
(AKR1B10) as the most up regulated gene in the liver of patients with AH.  The analysis 
also identified sorbitol dehydrogenase (SORD) to be significantly down-regulated in the 
	   6	  
setting of AH.  Therefore, we aim to determine the effects of ethanol and signaling 
factors on the mRNA expression of AKR1B10 and SORD in vitro and in vivo models. 
 
AKR1B10: 
AKR1B10 is a known gene that is located on chromosome 7 (2). The expression of 
AKR1B10 is highly induced in the cells of various cancers such as lung non-small-cell 
carcinoma and hepatocellular carcinoma (3). Since the enzyme exhibits broad substrate 
specificities toward various xenobiotics such as anti-tumor drugs or various endogenous 
compounds such as retinaldehyde, AKR1B10 may play an important role in tumor 
progression or drug resistance (3). It also has an important role in the sorbitol polyol 
pathway, an alternative pathway for glucose metabolism (4). Since AKR1B10 was up 
regulated in patients with AH, as the deep-sequencing identified, the expression was 
induced and studied in various cell models. These models include HepG2, VL-17a, mice, 
and Human hepatocytes, especially when exposed to tumor necrosis factor α-(TNFα), 
epidermal growth factor (EGF), and insulin. EGF and insulin have been previously 
shown to induce AKR1B10 expression (5). TNFα was explored, as it is highly involved in 
severe liver diseases, including alcoholic hepatitis. It is important to note that in mice, the 
mouse ortholog for AKR1B10 is AKR1B8(6) 
 
SORD 
SORD, a gene located on chromosome 15, codes for an enzyme that converts polyols into 
their corresponding ketoses (7). Together, SORD and aldose reductases constitute the 
sorbitol polyol pathway, which converts glucose to sorbitol and then sorbitol to 
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fructose(7).  The polyol pathway is hypothesized to play an important role in the 
progression and development of diabetes (7).  Since SORD was down regulated in patients 
with AH, the expression was induced and studied in various cell lines such as HepG2, 
VL-17a, primary human hepatocytes, and in a mouse model.   Specifically, the effect of 
TNFα, EGF, and insulin, and ethanol exposure on AKR1B10 and SORD mRNA 
expression was studied. 
 
Lieber-DeCarli Diet 
The Lieber-DeCarli diet was developed in 1982 as a method of ethanol exposure in 
rodent models. It is currently the most commonly used model for alcoholic liver injury (8). 
The administration of this diet in rodent models can result in mild steatosis, slight 
elevation of serum alanine transaminase (ALT) but little or no inflammation (8). This diet 
is suitable for exposing mice to ethanol in order to investigate the effects of AKR1B10 
up-regulation on hepatocytes.  
 
Sorbitol Polyol Pathway 
AKR1B10 and SORD are both genes that code for enzymes involved in the polyol 
pathway.   In the polyol pathway, glucose is metabolized into sorbitol via AKR1B10, and 
SORD then converts sorbitol to fructose (9). When produced inside the cell, sorbitol is 
sequestered and cannot leave.  In contrast, fructose is able to leave the cell via a fructose 
transporter (9).  Since AKR1B10 is up regulated and SORD is down regulated in patients 
with AH, we hypothesized that these patients may experience sorbitol accumulation in 
the hepatocytes. AKR1B10 over-expression could lead to increased sorbitol production 
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inside the cell while decreased SORD expression may prevent sorbitol degradation 
leading to intracellular sorbitol accumulation.  Since hepatocytes, unlike other cells in the 
body, do not have known sorbitol transporters, sorbitol accumulation could cause 
hepatocellular damage including osmotic and oxidative stress. 
In renal cells and erythrocytes, there is an enzyme called “sorbitol permease” which has 
the ability to remove excess sorbitol from the cell (10). Before the cell is lysed due to 
osmotic pressure, the sorbitol permease allows release of the sorbitol into the 
bloodstream. It is in response linearly to sorbitol concentration and is not affected by 
substances that normally block other sugar transporters (10). However, there has been no 
such mechanism found in the liver.  
 
Since it has been determined that AKR1B10 and SORD mRNA expression are altered in 
patients who present with alcoholic hepatitis, a major goal of the experiments detailed in 
this paper was to study the potential mechanisms underlying AKR1B10 and SORD 
mRNA expression in hepatocytes. In order to do so, AKR1B10 and SORD mRNA 
expression are studied in in vivo and in vitro models. The in vitro models used included 
HepG2 cells, primary human hepatocytes, and VL-17A cells. Both the primary human 
hepatocytes and HepG2 cells were used to study AKR1B10 and SORD mRNA induction 
in hepatocytes.  Human hepatocytes possess many of the functions lost in immortalized 
hepatocellular carcinoma lines and are a useful model for studying hepatocytes10. As 
insulin and EGF have proven to induce AKR1B10 expression6, and TNFα is involved in 
the progression of many hepatic disorders, human hepatocytes are to be exposed to each 
of these. HepG2 cells are a hepatocellular liver carcinoma cell line that was derived from 
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a liver biopsy of a 15-year-old Caucasian male11 and are commonly used to study 
hepatocytes and the progression of liver diseases. HepG2 cells are to be exposed to EGF, 
which will theoretically induce the expression of SORD and AKR1B10. Unlike HepG2, 
VL-17A cells possess enzymes that metabolize alcohol, such as alcohol dehydrogenase 
and CYP2E19. Thus, VL-17A cells are a useful for studying the effects of ethanol and 
ethanol metabolism in vitro.  For these studies, VL-17A cells will be used to determine 
changes in mRNA expression of AKR1B10 and SORD caused by ethanol exposure.  An 
in vivo model of ethanol exposure in mice was used to compliment the in vitro models 
used for these studies.  For the in vivo studies, mice were fed and ethanol containing 
Lieber DeCarli diet over the course of four weeks.  
Given the goals of our experiments, our main hypotheses were that 1) EGF, insulin, and 
TNFα can induce AKR1B10 and SORD mRNA expression in primary human 
hepatocytes 2) EGF can induce AKR1B10 and SORD mRNA expression in HepG2 cells, 
and 3) AKR1B10 mRNA expression will be up-regulated and SORD will be down-
regulated after ethanol exposure in VL-17A cells and in the liver of mice. A proposed 
mechanism for hepatocyte damage in AH is dysregulation of AKR1B10 and SORD 
mRNA expression, favoring the accumulation of sorbitol in hepatocytes.    
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III. METHODS 
Patient Samples: 
Seventeen patients admitted to the Liver Unit of the Hospital Clinic in Barcelona, Spain 
from 2007 to 2009 with features of alcoholic hepatitis were included as patient samples 
for this study (1). In addition, seven patients that were diagnosed with compensated liver 
disease, indicating that they had non-alcohol mediated cirrhosis, were included for 
analysis. For control purposes, samples from nine patients diagnosed with chronic 
hepatitis-C induced liver disease were also analyzed. These patients had HCV genotype 1 
and had not received previous antiviral treatment. The inclusion criterion has been 
described in previous studies (1). Liver biopsies from these patients were obtained using a 
trans-jugular approach. For all patients, an expert liver pathologist examined each 
specimen to confirm diagnosis. Portions of the biopsy were submerged into an RNA 
stabilization solution (Austin, Texas, USA) and subsequent mRNA isolation. All patients 
involved in the study gave informed consent and the protocol was conformed to the 
ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Ethics 
Committee of the Hospital Clinic of Barcelona (1).  
 
Mouse Models:  
The mice used for the study were a generous gift from the laboratory of Scott Magness 
(UNC Chapel Hill). All experimental procedures were reviewed and approved by the 
University of North Carolina at Chapel Hill Institutional Animal Care and Use 
Committee. Eight-week old C57BL6/J female mice were exposed to an ethanol-
containing Lieber-DeCarli diet, or pair fed control diet, for four weeks in order to create 
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an in vivo model of alcohol exposure, as described previously (8).  Briefly, ethanol fed 
mice were given a liquid diet (Dyets, Bethlehem, PA) that contained increasing 
concentrations of ethanol over a period of four weeks until a concentration of six percent 
ethanol was reached(8).  Control animals were pair fed an isocaloric control diet (8).  Mice 
were fed once per day between the hours of 4:30 and 5:30 PM and consumed 12 mL per 
mouse per day. Mice were kept on a 12-hour light/dark cycle and housed in temperature 
and humidity controlled rooms. At the time of sacrifice, mice were anesthetized and liver 
samples were collected for the analysis of AKR1B10 and SORD mRNA expression.  A 
fragment of liver tissue was immediately submerged in Trizol (ThermoFisher, Carlsbad, 
CA, USA) for RNA isolation. 
 
Cell Cultures 
All cells were maintained at 37 degrees C in a 5% CO2 environment.  HepG2 cells 
(ATCC, Rockville Maryland) and VL-17A cells (a generous gift from the Zeisel Lab, 
Kannapolis, NC) were cultured as previously described (11).  Specifically, cells were 
maintained in appropriate media and were passaged twice per week with Trypsin (Gibco, 
Grand Island, USA).  Primary human hepatocytes (Triangle Research Labs, North 
Carolina) were grown following the supplier’s protocol(12).   
 
HepG2 cells and primary human hepatocytes were exposed to EGF (50 ng/mL) for 24 
hours as described by others (5). VL-17A were exposed to 100 mM ethanol for 24 hours 
and Human hepatocytes, were exposed to EGF (50 ng/mL), insulin (10 mM), or TNFα 50 
ng/mL for 24 hours.  
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Cells were passaged using PBS (Gibco, Grand Island, USA) and trypsin.  RNA was 
isolated from the cells using Trizol (ThermoFisher, Carlsbad, CA, USA) following 
manufacturer’s protocol. 
 
RNA isolation and qPCR 
RNA was isolated from both animal and human cells using Trizol (ThermoFisher, 
Carlsbad, CA, USA) following manufacturer’s protocol. To isolate the mRNA, phenol: 
chloroform extraction was used. To determine the concentration and purity of RNA 
present in the samples, absorbance was measured at 260 and 280 nm, respectively, using 
a NanoDrop 1000. A cDNA reverse transcription kit (Applied Biosystems, Foster City, 
CA, USA) was used to reverse-transcribe mRNA.  For quantitative PCR analysis, cDNA 
was amplified for forty cycles using a StepOne PlusTM Real-Time PCR System (Applied 
Biosystems). Both mouse and human primers were used in analysis and were purchased 
from Applied Biosystems as kits (Foster City, CA). Mouse probes included: 
Mm03928990_g1 for 18S, Mm03048764 for AKR1B10, and Mm00455377_g1 for 
SORD. These probes were used for the in vivo model of ethanol exposure. Human probes 
included: Hs03928985_g1 for 18S, Hs01546975_gH for ARK1B10, and 
Hs00162091_m1 for SORD and were used for the in vitro models.  Results were 
normalized to 18S expression for animal and human samples. Gene expression was 
calculated using the ΔCT method. This method determines the amount of target gene, 
normalized to 18S, an endogenous reference gene, and relative to a calibrator (2-ΔΔCT).  
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Statistics 
Results of quantitative variables are expressed as the mean ± standard error of the mean. 
To analyze results, Prism by Graphpad software was used. Two-sample t-tests were 
performed and statistical significance was determined as p < 0.05. This value was set 
prior to the experiments.  
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IV. RESULTS 
AKR1B10 and SORD mRNA Expression in Patients with Alcoholic Hepatitis  
A previous study using microarray analysis identified AKR1B10 as the most highly up-
regulated gene in patients with alcoholic hepatitis (AH) (1).  That study also found that 
SORD was down-regulated in AH patients (1).  Therefore, using real-time qPCR analysis, 
we analyzed both hepatic AKR1B10 and SORD mRNA expression in a cohort of patients 
diagnosed with AH, non-alcoholic mediated cirrhosis, and hepatitis C virus. These results 
indicate that there is significant AKR1B10 overexpression and SORD under-expression 
in patients with alcoholic hepatitis, compared to controls and patients with other liver 
diseases, which included hepatitis-c and non-alcohol mediated cirrhosis. Patients with 
AH had a 220-fold increase when compared to controls and SORD had a 0.6 fold 
decrease (Figure 1).  
 
Figure 1.  Hepatic AKR1B10 and SORD mRNA expression in patients with liver 
diseases (*p<0.05 compared to all other groups 
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AKR1B10 and SORD mRNA Expression in HepG2 Cells  
AKR1B10 and SORD mRNA was analyzed in HepG2 cells, considering HepG2 cells 
originate from a hepatocellular carcinoma cell line and are widely used for the study of 
liver diseases (11). Cells were exposed to EGF, as EGF has shown to induce AKR1B10 
mRNA expression in other studies (5). EGF exposure caused a significant increase in 
AKR1B10 mRNA expression as it was increased by 1.5 fold in HepG2 cells (Figure 3).  
There was no significant change in SORD mRNA expression.  
 
 
Figure 2.  The effect of EGF exposure on AKR1B10 and SORD mRNA expression in 
HepG2 cells (*p<0.05 compared to all other groups) 
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AKR1B10 and SORD mRNA Expression in VL-17A Cells 
AKR1B10 and SORD mRNA expression were analyzed in VL-17A cells after exposure 
to 100 mM of ethanol for 24 hours. VL-17A cells are HepG2 cells that have been altered 
to express enzymes that play a key role in alcohol metabolism, ADH and CYP2E1(13). 
AKR1B10 mRNA expression was significantly increased 2.5 fold after exposure to 100 
mM ethanol for 24 hours.  Ethanol exposure did not cause a significant change in SORD 
mRNA expression (figure 4).  
 
 
Figure 3. The effect of 24 hour 100 mM ethanol exposure on AKR1B10 and SORD 
mRNA expression in VL-17A cells (*p<0.05 compared to all other groups) 
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AKR1B10 and SORD mRNA Expression in Human Hepatocytes  
AKR1B10 and SORD mRNA expression were determined in cryopreserved primary 
human hepatocytes, as human hepatocytes maintain some metabolic functions of 
hepatocytes that are lost in the immortalized hepatocellular carcinoma cell lines (i.e-
HepG2) (13).  The human hepatocytes were exposed to EGF or insulin, since previous 
published manuscripts indicate that EGF and insulin can induce AKR1B10 in HepG2 
cells (5).  Cells were exposed to TNFα, considering TNFα is highly involved in severe 
liver diseases, including alcoholic hepatitis. Results indicate that AKR1B10 is up-
regulated when exposed to EGF, but that there is no major change when exposed to 
insulin and TNFα. AKR1B10 had a 16-fold increase when exposed to EGF in 
comparison to other groups. There was also no significant change in SORD mRNA 
expression (figure 2).  
 
Figure 4. The Effect of EGF, insulin, TNFα  on AKR1B10 and SORD mRNA 
expression in primary human hepatocytes  (*p<0.05 compared to all other groups) 
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AKR1B10 and SORD mRNA Expression in Animal Models of Alcoholic Hepatitis  
Mice were fed an ethanol-containing diet or were pair-fed control diet for four weeks, 
according to the Lieber-DeCarli method (8).   AKR1B10 mRNA expression was not 
significantly changed by ethanol exposure (Figure 5).   SORD mRNA expression was 
significantly up-regulated in mice exposed to alcohol by 1.7 fold.  
 
 
Figure 5.  The effect of Ethanol Exposure on AKR1B10 and SORD mRNA 
Expression in Mice Models (*p<0.05 compared to all other groups) 
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V. DISCUSSION 
Alcohol over-consumption is a prevalent problem in today’s society. As alcohol is 
primarily metabolized in the liver, over-consumption can lead to a number of adverse 
effects, resulting in hepatic cell damage(1). Alcoholic hepatitis is an example of a rare 
condition that leads to the inflammation of the liver, usually after alcoholic liver disease 
is already present (1). Unfortunately, not much is known on the pathogenesis of alcoholic 
hepatitis.  Thus, a major goal of this study was to explore a potential mechanism 
underlying alcoholic hepatitis and find specific targets for therapy.  
Liver tissue from patients with AH was previously deep-sequenced by our 
research group. This study identified that AKR1B10 was the most up-regulated gene and 
that SORD was significantly under-expressed. In order to confirm these results and 
identify how AKR1B10 and SORD mRNA expression are altered in patients with liver 
conditions, seventeen liver samples from patients who presented with alcoholic hepatitis, 
non-alcohol mediated cirrhosis, and hepatitis-C induced liver diseases were collected and 
qPCR was performed in our study. AKR1B10 was significantly up regulated and SORD 
was significantly down-regulated in patients with alcoholic hepatitis (Figure 1). AH 
patients presented with a 220-fold increase in terms of AKR1B10 mRNA expression, in 
comparison to the control, and a 0.6 fold decrease for SORD mRNA expression (Figure 
1).  These findings were consistent with the previously performed experiments that 
involved the deep sequencing of liver tissue from patients with AH. They also indicate 
that AKR1B10 and SORD are likely involved in the progression of AH and should be 
investigated further.  
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As aforementioned, besides being up-regulated in those with alcoholic hepatitis, 
AKR1B10 is also highly expressed in patients with hepatocellular carcinoma and lung 
non-small-cell carcinoma, and may play a major role in tumor progression (3).  AKR1B10 
is also involved in the sorbitol polyol pathway, as it converts glucose to sorbitol (9). 
The SORD gene codes for a multitude of enzymes that play an integral role in 
converting polyols and their corresponding ketoses (7). Like ARK1B10, SORD, along 
with aldose reductase, is involved in the sorbitol polyol pathway, as it converts sorbitol to 
fructose (10).  
Considering both of these genes are involved in the sorbitol polyol pathway, it is 
possible that this pathway may play a role in the progression of alcoholic hepatitis. Since 
AKR1B10 is over-expression and SORD is under-expressed, there may be increased 
sorbitol accumulation in the hepatocytes. Since there is no known transporter in 
hepatocytes that can remove sorbitol, increased sorbitol production and a decrease in 
sorbitol degradation may lead to osmotic stress13.   
By using in vivo and in vitro models, we explored AKR1B10 and SORD mRNA 
expression in primary human hepatocytes and HepG2 cells, and determine what happens 
to expression when exposed to ethanol in VL-17A cells and mice. We hypothesized that 
TNFα, insulin, and EGF could induce expression and that ethanol could cause AKR1B10 
mRNA expression to be up-regulated and SORD to be down-regulated. This would be 
consistent with the idea that sorbitol may be accumulating in the cells, which is a 
potential mechanism for hepatocellular damage.  
After identifying that both ARK1B10 and SORD had altered mRNA expression 
in patients with alcoholic hepatitis (Figure 1), further experiments were performed to 
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explore AKR1B10 and SORD mRNA expression in other hepatocytes, such as HepG2 
cells (Figure 2). HepG2 cells are widely used for the study of liver diseases, and originate 
from a hepatocellular carcinoma cell line. Results indicate that, when exposed to EGF, 
AKR1B10 mRNA expression is increased by 1.5 fold in HepG2 cells. However, there 
seemed to be no significant change in SORD mRNA expression (Figure 3). These results 
also confirm studies that state AKR1B10 can be induced in the presence of EGF and 
demonstrated that AKR1B10 mRNA expression can be stimulated in various cell types. 
However, HepG2 cells are not the most similar to actual human liver cells and doing 
experiments with a more accurate cell model may present with different results.   
Since AKR1B10 was found to be inducible in the presence of EGF, it was 
possible that other cell models could be used to see if ethanol had any effect on 
AKR1B10 or SORD mRNA expression, since ethanol exposure is the a contributing 
factor to the development of alcoholic hepatitis. Thus, these genes were analyzed in VL-
17A cells, which are HepG2 cells that have been altered to express alcohol-metabolizing 
genes, ADH and CYP2E1 (11). Cells were exposed to 100 mM of ethanol for 24 hours, and 
results indicated a 2.5 fold increase for AKR1B10 mRNA expression, but no significant 
change for SORD mRNA expression (Figure 3). Unlike HepG2 cells, Vl-17A cells are 
more representative of actual human liver cells since they can metabolize alcohol, but are 
still not an ideal model for the study of hepatocytes. AKR1B10 up-regulation due to 
ethanol exposure in VL-17A cells indicate that ethanol may contribute to the over-
expression of AKR1B10 in AH.  
Similarly, AKR1B10 and SORD mRNA expression were studied in primary 
human hepatocytes, which are particularly useful for studying hepatocytes as they 
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maintain many of the metabolic functions of hepatocytes that are lost in other 
immortalized hepatocellular carcinoma cell lines10.  The primary human hepatocytes were 
exposed to TNFα, EGF, or insulin. According to previous research, AKR1B10 mRNA 
expression could be induced in HepG2 cells in the presence of either insulin or EGF. In 
addition, cells were exposed to TNFα, as TNFα is highly involved in the progression of 
various liver diseases.  When examining AKR1B10 and SORD mRNA expression in 
human hepatocytes, it is clear that there was significant change in AKR1B10 mRNA 
expression when exposed to EGF.  AKR1B10 has a 16-fold increase in comparison to 
other groups (Figure 4). These results confirmed previous studies that stated that 
AKR1B10 is induced in the presence of EGF (5) and were consistent with our hypothesis. 
They also demonstrated that EGF could be a potential regulator of AKR1B10 up-
regulation in patients with AH. Considering EGF is present in humans, it is possible that 
patients with higher levels of EGF are more susceptible to developing AH, which is 
important to experiment on further. SORD was unaffected, suggesting that EGF may not 
be the cause of SORD under-expression in patients with AH. In addition, results indicate 
that insulin and TNFα do not affect significantly affect the expression of AKR1B10 or 
SORD.  
Considering AKR1B10 mRNA expression in increased in patients with AH, an in 
vivo model of ethanol exposure was created to explore AKR1B10 and SORD mRNA 
expression. This is because in vivo and in vitro models are two complimentary methods 
of investigating what may cause AKR1B10 up-regulation and what effect it may have on 
hepatocytes.  Eight mice were pair-fed ethanol for four weeks, according to the Lieber-
DeCarli method (8). Results indicated that SORD was up-regulated by 1.7 and that there 
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was no significant change in AKR1B10 mRNA expression (Figure 5). These results are 
not consistent with any of the hypotheses in our study. This demonstrates that moderate 
alcohol exposure alone does not induce AKR1B10 expression or cause SORD under-
expression in the model studied. However, it is important to note that mice metabolize 
alcohol differently from humans and that human drinking patters should be applied to the 
mice models in order to create a more effective model.  
Overall, results from the experiments conducted, with the exception of the in vivo 
model, demonstrate no significant change in SORD expression. This could be due to the 
fact that the cell models that we utilized are not perfect models of actual hepatocytes, the 
experimental environment was not representative of the human body, and because there 
could be other factors that regulate SORD dysregulation besides EGF, insulin, ethanol, or 
TNFα. In addition, it is important to note that no experiments that we conducted 
demonstrated both an up-regulation of AKR1B10 and down-regulation of SORD, which 
does not seem consistent with the idea of sorbitol accumulation. This shows that there are 
other underlying multifactorial mechanisms that may lead to sorbitol accumulation. 
However, with the exception of the in vivo model of ethanol exposure, experiments 
showed a significant up-regulation of AKR1B10, which does indicate that AKR1B10 
may be a meaningful player in the mechanisms underlying alcoholic hepatitis.  
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VI. CONCLUSION 
In all, it is evident from the experiments conducted that AKR1B10 is inducible by 
EGF in HepG2 cells and in primary human hepatocytes, as by ethanol in VL-17A cells.  
These suggest that that EGF and ethanol may be involved in the over-expression of 
AKR1B10 in patients with AH. However, SORD regulation was not altered as expected 
in any of the results. Thus, for our future studies, it is important to identify additional 
stimuli that could dysregulate ARK1B10 or SORD expression, such as LPS. In addition, 
to mimic the human body environment, a co-culture can be performed with our particular 
cell model and Kupffer or stellate cells, which are both native to the liver. A logical next 
step is to perform addition in vitro ethanol exposure experiments, particularly in primary 
human hepatocytes, as they are very similar to actual human liver cells. Our in vivo 
model could be improved by creating an ethanol exposure model that is more similar to 
human drinking patterns. This could include exposing the mice to a greater concentration 
of ethanol or exposing them for a longer period of time.  To further investigate whether 
sorbitol accumulation can cause negative effects in patients with AH, sorbitol levels 
should be measured in the hepatocytes of those with alcoholic hepatitis.  
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